

Amarantus Bioscience Holdings, Inc.  
Form 8-K  
February 26, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 25, 2015**

**AMARANTUS BIOSCIENCE HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of incorporation or organization)

**333-148922**

(Commission File Number)

**26-0690857**

IRS Employer

Identification No.)

**655 Montgomery Street**

**Suite 900**

**94111**

**San Francisco, CA**

Edgar Filing: Amaranthus Bioscience Holdings, Inc. - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

**(408) 737-2734**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Other Events

### Item

**8.01** On February 25, 2015, a Stipulation of Dismissal with Prejudice in connection with Reginicin, Inc. v. Lonza Walkersville, Inc. et al Case No. 1:13-cv-3596 was filed in United States District Court for the District of New Jersey pursuant to the Settlement Agreement dated February 23, 2015 by and among Amarantus Bioscience Holdings, Inc., Lonza Group, Ltd., Lonza America, Inc. and Lonza Walkersville, Inc.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**AMARANTUS BIOSCIENCE  
HOLDINGS, INC.**

Date: February 26, 2015 By: /s/ Gerald E. Commissiong

Name: Gerald E.

Commissiong

Title: Chief Executive

Officer